Thu, Jul 10, 2014, 10:37 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Zalicus Inc. Message Board

chevelle_69 32 posts  |  Last Activity: Jun 20, 2014 9:41 AM Member since: Feb 20, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • chevelle_69@rocketmail.com chevelle_69 Jun 20, 2014 9:41 AM Flag

    Hey Tab and Slugger! Just checking in....been a while! Too many kid's activities and my job have blurred my days! Hope you guys are doing well!

  • Reply to

    Hey Numnuts - Z944 is moving forward

    by ctbradley11 May 22, 2014 8:42 AM
    chevelle_69@rocketmail.com chevelle_69 May 22, 2014 4:10 PM Flag

    Translation of today's PR:

    Welcome on th' poop deck me ship I gunna pillage more 'o ye doubloons.

  • Reply to

    8 MILLION FOR cHTS

    by tabecounted1 May 15, 2014 1:45 PM
    chevelle_69@rocketmail.com chevelle_69 May 19, 2014 11:54 AM Flag

    Holding multiple bags right now....haven't been too excited about any of my holdings. Combine that with no play time at work = not spending too much time on yahoo mb (and googling/digging for info!). Definitely looking forward to some better days ahead!

  • Reply to

    WHATS GOING ON WITH ZLCS

    by mddougherty86 May 7, 2014 12:00 PM
    chevelle_69@rocketmail.com chevelle_69 May 8, 2014 7:22 AM Flag

    Z is doing what Z does...the dues man is collecting.

  • Reply to

    OT: SYN

    by chevelle_69 Apr 26, 2014 10:07 AM
    chevelle_69@rocketmail.com chevelle_69 Apr 30, 2014 8:10 AM Flag

    Conference call today and some clarification:

    In this Phase II study, women receiving oral Trimesta plus injectable Copaxone(R) demonstrated a statistically significant 47 percent decrease in annualized MS relapse rate in the first 12 months of treatment compared to women receiving placebo plus Copaxone (p=0.0306), and a 32 percent decrease in annualized relapse rate at 24 months (p=0.1527). Patients in both treatment arms demonstrated improved scores on the Expanded Disability Status Scale (EDSS) compared to baseline. Cognitive function test scores, as measured by the Paced Auditory Serial Addition Test (PASAT), in women receiving Trimesta plus Copaxone also improved compared to baseline and were significantly different from placebo plus Copaxone at 12 months.

  • chevelle_69@rocketmail.com by chevelle_69 Apr 30, 2014 7:04 AM Flag

    In this Phase II study, women receiving oral Trimesta plus injectable Copaxone® demonstrated a statistically significant 47 percent decrease in annualized MS relapse rate in the first 12 months of treatment compared to women receiving placebo plus Copaxone (p=0.0306), and a 32 percent decrease in annualized relapse rate at 24 months (p=0.1527). Patients in both treatment arms demonstrated improved scores on the Expanded Disability Status Scale (EDSS) compared to baseline. Cognitive function test scores, as measured by the Paced Auditory Serial Addition Test (PASAT), in women receiving Trimesta plus Copaxone also improved compared to baseline and were significantly different from placebo plus Copaxone at 12 months.

  • Reply to

    OT: SYN

    by chevelle_69 Apr 26, 2014 10:07 AM
    chevelle_69@rocketmail.com chevelle_69 Apr 30, 2014 6:58 AM Flag

    Seems to be some confusion about the 2nd year numbers:

    The Phase II, double-blinded, placebo-controlled trial randomized 158 women with relapsing-remitting MS at 16 sites across the U.S. Among topline results, women receiving Trimesta plus Copaxone demonstrated a statistically significant 47 percent decrease in annualized MS relapse rate in the first 12 months of treatment as compared to women receiving placebo plus Copaxone. In addition, a significant improvement in cognitive function was observed at 12 months as measured by Paced Auditory Serial Addition Test (PASAT) scores. After 24 months of treatment, the reduction in relapse rate persisted in favor of the Trimesta plus Copaxone treatment group compared to the Copaxone plus placebo group (32 percent). Both treatment groups exhibited improvement in measures of cognitive function at 24 months. Treatment was safe and well tolerated with no evidence of adverse effects on breast or uterus.

  • Reply to

    OT: SYN

    by chevelle_69 Apr 26, 2014 10:07 AM
    chevelle_69@rocketmail.com chevelle_69 Apr 29, 2014 4:25 PM Flag

    ...smoking crack today...relapse rate after 2 years not as good as the 1st year. 47% decrease to 32%

  • Reply to

    OT: SYN

    by chevelle_69 Apr 26, 2014 10:07 AM
    chevelle_69@rocketmail.com chevelle_69 Apr 29, 2014 4:23 PM Flag

    Relapse rate in second year not nearly as good after 2 years.....so much for averaging down on my other positions. lol Oh well, it is what it is. Guess I need positive results from INO and VGX-3100.

  • Reply to

    OT: SYN

    by chevelle_69 Apr 26, 2014 10:07 AM
    chevelle_69@rocketmail.com chevelle_69 Apr 29, 2014 4:15 PM Flag

    Not sure....guess the results weren't as good as hoped for.

  • Reply to

    OT: SYN

    by chevelle_69 Apr 26, 2014 10:07 AM
    chevelle_69@rocketmail.com chevelle_69 Apr 29, 2014 3:57 PM Flag

    Positive results and not much of a reaction.

  • Reply to

    ARSEP in Paris

    by prospern23 Apr 27, 2014 10:56 PM
    chevelle_69@rocketmail.com chevelle_69 Apr 27, 2014 11:02 PM Flag

    Looking at last year's program there is some sort of Teva connection (large Copaxone ad). Links on are iHuB and ST

  • chevelle_69@rocketmail.com by chevelle_69 Apr 26, 2014 10:07 AM Flag

    Holding through Trimesta results Tuesday.....need positive results so I can sell and average down on everything else I'm holding! lol Wish me luck!

  • Reply to

    reverse split

    by hidin_from_feds Apr 25, 2014 8:42 AM
    chevelle_69@rocketmail.com chevelle_69 Apr 25, 2014 8:47 AM Flag

    Synovus Financial Corp

  • chevelle_69@rocketmail.com chevelle_69 Apr 23, 2014 8:09 AM Flag

    Would they need to meet with Piper to discuss VGX rights offering?

  • chevelle_69@rocketmail.com chevelle_69 Apr 20, 2014 7:51 AM Flag

    bump over the effin trash

  • chevelle_69@rocketmail.com by chevelle_69 Apr 19, 2014 12:18 PM Flag

    Idera CEO says momentum remains strong despite stock declines

    Since becoming the Massachusetts drug developer whose shares rose faster than any other in 2013, Idera Pharmaceuticals has seen some pullback along with the rest of the market so far this year. But CEO Sudhir Argawal says everything remains on track with the company’s plans to have an approved drug as soon as 2017.

  • chevelle_69@rocketmail.com chevelle_69 Apr 18, 2014 10:39 AM Flag

    it is generally believed that the advances in DNA vaccine technology will offer customized and
    tailored vaccines to any disease in the future, representing an important component of next generation of proph-
    ylactic and therapeutic vaccines, efficient and economically accessible to peoples worldwide.

  • chevelle_69@rocketmail.com chevelle_69 Apr 18, 2014 10:04 AM Flag

    Sadly, until now no licensed human DNA vaccines exist, but the results obtained with the commercialized
    veterinary vaccines and the various human clinical trials that are under study are increasing the reliability of this
    vaccine platform, greatly raising hopes for the successful development of human vaccines and therapies. How-
    ever, a lot of effort and work is still necessary to improve the different DNA vaccine platforms to certify their
    safety and immunological efficiency.

  • A HIV-1 vaccine clinical trial phase I study was performed in healthy HIV-1–uninfected adults using the
    PENNVAX®-B DNA vaccine (PV is a mixture of 3 expression plasmids encoding HIV-1 Clade B Env, Gag, and
    Pol) and a DNA plasmid expressing human interleukin 12 (IL-12). Cellular immune responses were analysed
    after four intramuscular vaccine administration or three intramuscular administrations by electroporation. This
    trial showed that this vaccine was safe and well tolerated by patients and that the administration of PV and IL-12
    by electroporation had a significant dose-sparing effect and provided higher immunogenicity to that observed in
    the trial without electroporation, showing the power of combining DNA approaches to generate stronger im-
    mune responses in humans

ZLCS
1.16-0.02(-1.69%)Jul 10 3:57 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.